Related Experiment Video
Updated: Jul 16, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
Visual mismatch negativity highlights abnormal preattentive visual processing in Alzheimer's disease
1Department of Care of the Elderly, The BRACE Centre, University of Bristol, Blackberry Hill Hospital, Bristol, UK.
Neuroreport
|June 2, 2006
Summary
This study investigated age-related changes in visual mismatch negativity (vMMN) and Alzheimer's disease. Findings suggest fatigue does not cause vMMN decline in aging, but Alzheimer's patients show initial refractoriness to stimulus change.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Gerontology
Background:
- Mismatch negativity (MMN) amplitude decreases with normal aging and in Alzheimer's disease (AD).
- Theories suggest MMN reduction in AD may stem from fatigue rather than neuronal decline.
Purpose of the Study:
- To test the fatigue hypothesis by examining visual MMN (vMMN) changes over time in normal aging and AD.
- To differentiate between fatigue and other mechanisms underlying vMMN decline in these populations.
Main Methods:
- Measured visual mismatch negativity (vMMN) responses in older adults and individuals with Alzheimer's disease.
- Assessed the impact of time on task (stimulus repetition) on vMMN amplitude.
Main Results:
- In normally aging adults, vMMN amplitude decreased but was unaffected by time on task, refuting the fatigue hypothesis.
- In Alzheimer's disease, vMMN was initially absent but emerged with stimulus repetition, contradicting the fatigue hypothesis and suggesting initial refractoriness.
Conclusions:
- Fatigue is unlikely to explain vMMN amplitude reduction in normal aging.
- Alzheimer's disease is characterized by an initial refractoriness to stimulus change, not fatigue, impacting vMMN.
- These findings highlight distinct neural mechanisms underlying cognitive changes in aging and AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:12Visual Agnosia
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round end"...
01:24Prosopagnosia
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...